RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:71

Chylomicron retention disease

low confidenceDisorder

Also known as: Anderson disease · CMRD · CRD

Publications

1,122

Trials

0

Interventional, condition-specific

Researchers

1,119

Distinct authors in sample

Gene link

SAR1B

Strong

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

Chylomicron retention disease (CRD) is a type of familial hypocholesterolemia characterized by malnutrition, , growth failure, vitamin E deficiency and hepatic, neurologic and ophthalmologic complications.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

chylomicron retention disease

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

No matched interventional trial, but a gene association and an animal model are on record — often described as translation-ready / stalled at the clinical step.

  1. Gene identifiedPresent

    Strong — SAR1B

  2. LiteraturePresent

    1,122 matched papers (759 in last 10 years) Source

  3. Phenotype characterisedPresent

    34 HPO annotations (e.g. Decreased circulating LDL-C concentration; Hypocholesterolemia; Accumulation of lipid droplets in small-bowel enterocytes) Source

  4. Animal modelPresent

    5 genotype models (Danio rerio, Mus musculus) Source

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (SAR1B).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

34

Associated phenotypes · MONDO:0009528

  • Decreased circulating LDL-C concentration
  • Hypocholesterolemia
  • Accumulation of lipid droplets in small-bowel enterocytes
  • Vomiting
  • Impaired vibratory sensation

Showing 5 of 34 — open Monarch for the full list.

Animal models (Monarch / Alliance)

5

Model associations linked to this Mondo ID

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

2

Drugs / clinical candidates · MONDO_0009528

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

1,122

1,122 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

1,122 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

759 in the last 10 years · low confidence

Phrase hits: 348 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,119

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Levy E10 papers · 2024

    Research Centre, CHU-Sainte-Justine, and Université de Montréal, Montreal, Québec, Canada (Dr Levy).

    Papers in Europe PMC
  2. 02
    Wang X9 papers · 2026

    State Key Laboratory of Membrane Biology, Peking University, Beijing, China. Xiao_WANG@pku.edu.cn.

    Papers in Europe PMC
  3. 03
    Zhang Y9 papers · 2026

    Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China.

    Papers in Europe PMC
  4. 04
    Spahis S8 papers · 2024

    Research Centre, CHU Ste-Justine, Université de Montréal, Montreal, QC, Canada.

    Papers in Europe PMC
  5. 05
    Peretti N7 papers · 2024

    Department of Pediatric Nutrition, Gastroenterology and Hepatology, Hôpital Femme Mère Enfant de Lyon, 59 bd Pinel, 69677, Bron, France; Hospices Civils de Lyon, France. Electronic address: noel.peretti@chu-lyon.fr.

    Papers in Europe PMC
  6. 06
    Wang J7 papers · 2025

    Department of Translational Medicine, Amoy Diagnostics, Xiamen, Fujian, China.

    Papers in Europe PMC
  7. 07
    Li X6 papers · 2026

    State Key Laboratory of Meat Quality Control and Cultured Meat Development, Key Laboratory of Meat Processing, Ministry of Agriculture, Key Lab of Meat Processing and Quality Control, Ministry of Education, Jiangsu Collaborative Innovation Center of Meat Production and Processing, College of Food Science and Technology, Nanjing Agricultural University, Nanjing 210095, China.

    Papers in Europe PMC
  8. 08
    Wang Y6 papers · 2026

    School of Basic Medicine, Shanxi Medical University, Taiyuan, China.

    Papers in Europe PMC
  9. 09
    Chen XW5 papers · 2026

    State Key Laboratory of Membrane Biology, Peking University, Beijing, China. xiaowei_chen@pku.edu.cn.

    Papers in Europe PMC
  10. 10
    Chen Y5 papers · 2024

    Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 40 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (40)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Chylomicron retention disease — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Chylomicron retention disease" OR "Anderson disease") OR ("SAR1B" OR "SAR1B syndrome" OR "SAR1B-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Chylomicron retention disease" OR "Anderson disease"

Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: CMRD; CRD

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 2 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1122) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-26T12:18:17.130Z